• Hunter Capital RTO 1’s proposed reverse acquisition of ResoTher advanced after RTP-026 Phase 2a top-line results met a key condition.
• Remaining condition requires ResoTher to raise or otherwise secure at least SEK 65 million; combined with ~SEK 15 million raised totals ~SEK 80 million.
• Phase 2a showed median LVEF improved 8 percentage points in both RTP-026 dose groups at Day 90, versus 2.5 points for placebo.
• Parties will continue the transaction process under the LOI, subject to definitive documentation and completion steps.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hunter Capital RTO 1 AB (publ) published the original content used to generate this news brief via Cision (Ref. ID: 202609140745BITN____UKPR__SV_20260914-BIT-9999-0) on September 14, 2026, and is solely responsible for the information contained therein.